CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days
The Indian Hotels Company Ltd. 24/08/2023401.85517.9007/02/2024 28.88% 167 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Index trend and stocks in action February 12, 2019
Karan Dsij
/ Categories: Trending, Pre Morning

Index trend and stocks in action February 12, 2019

Nifty started the week on a negative note and, on the downside, it went on to test its 200-day moving average. However, in the last leg of trading, buying emerged around the crucial moving average and Nifty trimmed some of its losses to ultimately close with a loss of 0.50 per cent below the 10,900 mark. The price action formed a bear candle with a minor lower shadow. Going ahead, the level of 10,850-10,858 is likely to act as an immediate support zone for the index as the 200-day moving average and Monday’s session low is placed in this region. On the upside, Nifty needs to move beyond the level of 10,950 as this would bring back some optimism in the index.  

Axis Bank: The Specified Undertaking of the United Trust of India (SUUTI) will sell up to 5,07,59,949 (representing 1.98 per cent of paid-up equity) equity shares of Axis Bank on February 12 and 13, with an option to additionally sell 2,63,37,187 (1.02 per cent) equity shares through offer for sale. 
  
Alembic Pharmaceuticals: Aleor Dermaceuticals Ltd, a 60:40 joint venture between Alembic Pharmaceuticals Ltd and Orbicular Pharmaceutical Technologies Pvt. Ltd, has completed United States Food and Drug Administration (USFDA) inspection at its formulation manufacturing facility located at Karakhadi in Gujarat with two observations.  

Previous Article Markets may open on a cautious note ahead of release of key macro data
Next Article Axis Bank OFS to open for retail investors on Wednesday
Print
603 Rate this article:
5.0
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR